Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Gross Profit (2016 - 2025)

Adma Biologics (ADMA) has disclosed Gross Profit for 13 consecutive years, with $88.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Profit rose 40.23% year-over-year to $88.8 million, compared with a TTM value of $292.8 million through Dec 2025, up 33.35%, and an annual FY2025 reading of $292.8 million, up 33.35% over the prior year.
  • Gross Profit was $88.8 million for Q4 2025 at Adma Biologics, up from $75.6 million in the prior quarter.
  • Across five years, Gross Profit topped out at $88.8 million in Q4 2025 and bottomed at -$1.7 million in Q1 2021.
  • Average Gross Profit over 5 years is $31.9 million, with a median of $20.7 million recorded in 2023.
  • The sharpest move saw Gross Profit tumbled 114.5% in 2021, then skyrocketed 2406.02% in 2022.
  • Year by year, Gross Profit stood at $3.5 million in 2021, then soared by 303.76% to $14.2 million in 2022, then skyrocketed by 119.27% to $31.1 million in 2023, then skyrocketed by 103.73% to $63.3 million in 2024, then skyrocketed by 40.23% to $88.8 million in 2025.
  • Business Quant data shows Gross Profit for ADMA at $88.8 million in Q4 2025, $75.6 million in Q3 2025, and $67.2 million in Q2 2025.